Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008300137> ?p ?o ?g. }
- W3008300137 endingPage "35" @default.
- W3008300137 startingPage "35" @default.
- W3008300137 abstract "Oxazolidinones are antibiotics that inhibit protein synthesis by binding the 50S ribosomal subunit. Recently, numerous worldwide researches focused on their properties and possible involvement in cancer therapy have been conducted. Here, we evaluated in vitro the antiproliferative activity of some 5-(carbamoylmethylene)-oxazolidin-2-ones on MCF-7 and HeLa cells. The tested compounds displayed a wide range of cytotoxicity on these cancer cell lines, measured by MTT assay, exhibiting no cytotoxicity on non-tumorigenic MCF-10A cells. Among the nine tested derivatives, four displayed a good anticancer potential. Remarkably, OI compound showed IC50 values of 17.66 and 31.10 µM for MCF-7 and HeLa cancer cells, respectively. Furthermore, we assessed OI effect on the cell cycle by FACS analysis, highlighting a G1 phase arrest after 72 h, supported by a low expression level of Cyclin D1 protein. Moreover, mitochondrial membrane potential was reduced after OI treatment driven by high levels of ROS. These findings demonstrate that OI treatment can inhibit MCF-7 and HeLa cell proliferation and induce apoptosis by caspase-9 activation and cytochrome c release in the cytosol. Hence, 5-(carbamoylmethylene)-oxazolidin-2-ones have a promising anticancer activity, in particular, OI derivative could represent a good candidate for in vivo further studies and potential clinical use." @default.
- W3008300137 created "2020-03-06" @default.
- W3008300137 creator A5002681020 @default.
- W3008300137 creator A5014579151 @default.
- W3008300137 creator A5021882845 @default.
- W3008300137 creator A5028328541 @default.
- W3008300137 creator A5035655856 @default.
- W3008300137 creator A5041654806 @default.
- W3008300137 creator A5042465788 @default.
- W3008300137 creator A5042986919 @default.
- W3008300137 creator A5047846477 @default.
- W3008300137 creator A5075093036 @default.
- W3008300137 creator A5086195755 @default.
- W3008300137 date "2020-02-18" @default.
- W3008300137 modified "2023-09-26" @default.
- W3008300137 title "5-(Carbamoylmethylene)-oxazolidin-2-ones as a Promising Class of Heterocycles Inducing Apoptosis Triggered by Increased ROS Levels and Mitochondrial Dysfunction in Breast and Cervical Cancer" @default.
- W3008300137 cites W165060328 @default.
- W3008300137 cites W1876525511 @default.
- W3008300137 cites W1897724420 @default.
- W3008300137 cites W1902738905 @default.
- W3008300137 cites W1964772853 @default.
- W3008300137 cites W1966257322 @default.
- W3008300137 cites W1974277291 @default.
- W3008300137 cites W1976897494 @default.
- W3008300137 cites W1977178308 @default.
- W3008300137 cites W1980806488 @default.
- W3008300137 cites W1981883990 @default.
- W3008300137 cites W1993105964 @default.
- W3008300137 cites W1999251997 @default.
- W3008300137 cites W2000473810 @default.
- W3008300137 cites W2028743750 @default.
- W3008300137 cites W2033180510 @default.
- W3008300137 cites W2041182780 @default.
- W3008300137 cites W2046024621 @default.
- W3008300137 cites W2046589768 @default.
- W3008300137 cites W2051966197 @default.
- W3008300137 cites W2064442490 @default.
- W3008300137 cites W2065430267 @default.
- W3008300137 cites W2071333117 @default.
- W3008300137 cites W2073961099 @default.
- W3008300137 cites W2080452140 @default.
- W3008300137 cites W2086828029 @default.
- W3008300137 cites W2098712005 @default.
- W3008300137 cites W2101575450 @default.
- W3008300137 cites W2117692326 @default.
- W3008300137 cites W2124788857 @default.
- W3008300137 cites W2126221698 @default.
- W3008300137 cites W2129260125 @default.
- W3008300137 cites W2135331361 @default.
- W3008300137 cites W2143036691 @default.
- W3008300137 cites W2144277227 @default.
- W3008300137 cites W2149343603 @default.
- W3008300137 cites W2149967205 @default.
- W3008300137 cites W2154346380 @default.
- W3008300137 cites W2159640574 @default.
- W3008300137 cites W2172106590 @default.
- W3008300137 cites W2183070954 @default.
- W3008300137 cites W2283072231 @default.
- W3008300137 cites W2298195942 @default.
- W3008300137 cites W2309934028 @default.
- W3008300137 cites W2345381093 @default.
- W3008300137 cites W2469055102 @default.
- W3008300137 cites W2469858438 @default.
- W3008300137 cites W2563930399 @default.
- W3008300137 cites W2579021825 @default.
- W3008300137 cites W2596100771 @default.
- W3008300137 cites W2738754485 @default.
- W3008300137 cites W2762611215 @default.
- W3008300137 cites W2767078779 @default.
- W3008300137 cites W2772743504 @default.
- W3008300137 cites W2773927148 @default.
- W3008300137 cites W2790599519 @default.
- W3008300137 cites W2792884505 @default.
- W3008300137 cites W2793972506 @default.
- W3008300137 cites W2801487934 @default.
- W3008300137 cites W2807372557 @default.
- W3008300137 cites W2888180412 @default.
- W3008300137 cites W2897042022 @default.
- W3008300137 cites W2950526259 @default.
- W3008300137 cites W2958932183 @default.
- W3008300137 cites W2989442756 @default.
- W3008300137 cites W2990334959 @default.
- W3008300137 cites W2076812144 @default.
- W3008300137 doi "https://doi.org/10.3390/biomedicines8020035" @default.
- W3008300137 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7168333" @default.
- W3008300137 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32085547" @default.
- W3008300137 hasPublicationYear "2020" @default.
- W3008300137 type Work @default.
- W3008300137 sameAs 3008300137 @default.
- W3008300137 citedByCount "21" @default.
- W3008300137 countsByYear W30083001372020 @default.
- W3008300137 countsByYear W30083001372021 @default.
- W3008300137 countsByYear W30083001372022 @default.
- W3008300137 countsByYear W30083001372023 @default.
- W3008300137 crossrefType "journal-article" @default.
- W3008300137 hasAuthorship W3008300137A5002681020 @default.
- W3008300137 hasAuthorship W3008300137A5014579151 @default.
- W3008300137 hasAuthorship W3008300137A5021882845 @default.